Literature reports have also confirmed that in ovarian cancer, USP35 can directly de-ubiquitinate and inactivate STING, thereby enhancing the chemoresistance of ovarian cancer cells to chemotherapy drugs and promoting tumor development [16]. This evidence concerns the gene USP35 and ovarian carcinoma.